Method of treating delayed healing of a wound associated with diabetes

a diabetes and wound technology, applied in the field of wound treatment, can solve the problems of affecting the healing process of wounds, affecting the regeneration of injured tissue, and none of these therapies, however, are completely effective, so as to promote the healing of delayed wounds, prevent and/or reverse premature cellular senescence, and promote wound healing.

Inactive Publication Date: 2015-12-10
KUWAIT UNIV
View PDF5 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0011]The method of treating delayed healing of a wound associated with diabetes includes administering to the wound a composition comprising an anti-senescence compound and a pharmaceutically acceptable carrier. The anti-senescence compound may be 18α-Glycyrrhetinic acid, a Caveolin-1 (Cav-1) inhibitory compound, or a Polymerase I Transcript Release Factor (PTRF-1) inhibitory compound. The anti-senescence compound may be effective in preventing and / or reversing premature cellular senescence. The anti-senescence compound may be effective in promoting healing of a wound, e.g., a delayed or incompletely healed wound. The anti-senescence compound may be effective in promoting healing of a delayed healing wound or chronic wound of a diabetic patient, such as a diabetic ulcer or venous ulcer.

Problems solved by technology

However, in some cases, certain disorders, such as diabetes mellitus, or physiological insult disturbs the wound healing process.
These cells can be exploited by the tumor microenvironment to limit the progression of certain cancer types, but they may also have a detrimental influence on injured tissue regeneration.
None of these therapies, however, is completely effective, as each type suffers from its own disadvantages.
Moist wound therapy, for example, is known to promote fibroblast and keratinocyte proliferation and migration, collagen synthesis, early angiogenesis and wound contraction, but unfortunately all moist dressings cause fluid retention, and most of them require secondary dressings, making them difficult to use with exudative wounds.
Bio-engineered tissue and artificial skin coverings are presently being researched and have not yet reached a state where they provide a true substitute for human skin.
Although promising, the technique is invasive and also is still, at present, being studied for safety and effectiveness.
In spite of a very straightforward mechanism of action, there are many inconsistent results of negative pressure wound therapy studies.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method of treating delayed healing of a wound associated with diabetes
  • Method of treating delayed healing of a wound associated with diabetes
  • Method of treating delayed healing of a wound associated with diabetes

Examples

Experimental program
Comparison scheme
Effect test

example 1

Senescence-Like Features and a Reduction in the Maintenance of Cellular Redox Balance in DFs and OD-CFs

[0083]Control (CFs, n=3), diabetic (DFs, n=4), and oxidatively stressed control fibroblasts (OS-CFs, i.e., fibroblasts that were exposed to hydrogen peroxide, 150 μM for three passages; n=4) were assessed for the presence of key biomarkers of cellular senescence. SA-β-gal activity was assessed by either staining cells with a chromogenic X-gal-based cocktail solution and visualizing the blue coloration of the cytoplasm by light microscopy or by incubating cellular protein extracts with MUG fluorogenic substrate and determining the rate of conversion to the fluorescent 4-MU product with a fluorometer. pH2AX contents were either visualized by immunofluorescence staining assay using Texas Red-tagged goat anti-rabbit IgG as the secondary antibody, or quantified by a DNA damage assay kit. Cells were seeded (N0) in DMEM supplemented with 10% FCS and were harvested at confluence (Nf). The ...

example 2

DFs and OS-CFs Exhibited a Significant Increase in Caveolin-1 Expression and Attenuation in Growth Factor Actions

[0085]Control (n=3), diabetic (n=4), and oxidatively stressed control fibroblasts (e.g., control fibroblasts exposed to hydrogen peroxide, 150 μM for three passages; n=4) were used to assess caveolin-1 expression and the actions of growth factors. Caveolin-1 protein expression and PDGF-induced phosphorylation of Akt (20 min) and ERK (10 min) in 24-hr serum starved fibroblasts were determined using a Western-blotting-based technique. A proliferation index encompassing BrdU incorporation into DNA and cell cycle progression was evaluated in response to various growth factors (e.g., IGF, 50 ng; PDGF, 1 nM; EGF, 100 ng) in 24-hr serum starved fibroblast. An in vitro wound-healing model conducted by scratching starved confluent cultured fibroblasts with a pipette tip was used to monitor the impact of PDGF on cell migration. Most of the assays were performed in triplicate, and t...

example 3

Effects of Caveolin-1 Overexpression and Deficiency on Cellular Senescence and Key Fibroblast Functions Essential for Wound Healing

[0086]CFs were transfected with caveolin-1-pCMV(pCMV-Cav-1) or its vector control (pCMV-GRP), whereas DFs were rendered caveolin-1 deficient (Cav-1 siRNA) using siRNA-based technique. Transfection efficiency in both cases was confirmed using Taq-Man real-time PCR and Western blotting. After culturing for 48 hrs, cells were assessed in terms of senescence biomarkers, as in the case of SA-β-gal activity (fluorescence-based assay kit), pH2AX contents (fluorescence-based assay kit), and the protein expression of p53 (western blotting) and p21 (Western blotting) using fluorescence-based assay kits or Western blotting. Similarly, pCMV-Cav-1 and Cav-1 siRNA were also evaluated in the context of PDGF actions on p-Akt levels and key fibroblasts functions essential for wound healing, including BrdU incorporation into DNA (spectrophotometer-based assay kit) and cel...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
optical densityaaaaaaaaaa
pHaaaaaaaaaa
pHaaaaaaaaaa
Login to view more

Abstract

The method of treating delayed healing of a wound associated with diabetes includes administering to the wound a composition comprising an anti-senescence compound and a pharmaceutically acceptable carrier. The anti-senescence compound may be 18α-Glycyrrhetinic acid, a Caveolin-1 (Cav-1) inhibitory compound, or a Polymerase I Transcript Release Factor (PTRF-1) inhibitory compound. The anti-senescence compound may be effective in preventing and / or reversing premature cellular senescence. The anti-senescence compound may be effective in promoting healing of a wound, e.g., delayed or incompletely healed wound. The anti-senescence compound may be effective in promoting healing of a delayed healing wound or chronic wound of a diabetic patient, such as a diabetic ulcer or venous ulcer.

Description

BACKGROUND OF THE INVENTION[0001]1. Field of the Invention[0002]The present invention relates to the treatment of wounds, and particularly to a method of treating delayed healing of a wound associated with diabetes, and particularly premature cellular senescence induced by diabetes.[0003]2. Description of the Related Art[0004]Diabetic ulcers, such as diabetic foot ulcers, are a major complication of diabetes mellitus. Diabetic foot ulcers, in particular, occur in 15% of all patients with diabetes and precede 84% of all lower leg amputations. Major increases in mortality among diabetic patients, observed over the past 20 years, is considered to be due to the development of macro- and micro-vascular complications, including failure of the wound healing process.[0005]Wound healing is an innate mechanism of action that works reliably most of the time. A key feature of wound healing is stepwise repair of lost extracellular matrix (ECM), which forms the largest component of the dermal ski...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/19C12N15/113
CPCA61K31/19C12N15/113C12N2310/3233C12N2310/14C12N2310/11A61K31/56
Inventor BITAR, MILAD S.AL-MULLA, FAHD
Owner KUWAIT UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap